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Abstract
Purpose The underlying biological mechanisms of the
frequent exacerbator phenotype of COPD remain unclear.
We compared systemic neutrophil function in COPD
patients with or without frequent exacerbations.
Methods Whole blood from COPD frequent exacerbators
(defined as C2 moderate–severe exacerbations in the pre-
vious 2 years) and non-exacerbators (no exacerbations in
the preceding 2 years) was assayed for neutrophil function.
Neutrophil function in healthy ex-smoking volunteers was
also measured as a control (reference) group.
Results A total of 52 subjects were included in this study:
26 frequent exacerbators, 18 non-exacerbators and 8
healthy controls. COPD frequent exacerbators had blunted
blood neutrophil fMLP-stimulated oxidative burst com-
pared to both non-exacerbators (p\ 0.01) and healthy
controls (p\ 0.001). There were no differences between
COPD frequent exacerbators and non-exacerbators in
blood neutrophil PMA-stimulated oxidative burst, but both
COPD groups had reduced responses compared to healthy
controls (p\ 0.001). Bacterial-stimulated neutrophil
degranulation was greater in frequent exacerbators than
non-exacerbators (p\ 0.05).
Conclusion This study is the first to report aberrant
receptor-mediated blood neutrophil function in the frequent
exacerbator of COPD.
Keywords Chronic obstructive pulmonary disease 
Elastase  Granulocyte  Polymorphonuclear leukocytes 
Reactive oxygen species
Abbreviations
a1-PI Alpha 1-proteinase inhibitor
CL Chemiluminescence
eCO Exhaled carbon monoxide
fMLP Formyl-methionyl-leucyl-phenylalanine
HBSS Hank’s balanced salt solution
NADPH Nicotinamide adenine dinucleotide phosphate
NE Neutrophil elastase
PMA Phorbol-12-myristate-13-acetate
ROS Reactive oxygen species
RLU Relative light units
TLR Toll-like receptor
Introduction
Chronic obstructive pulmonary disease (COPD) is char-
acterised by a progressive decline in lung function and
associated with chronic aberrant inflammatory responses of
the lung and airways to noxious stimuli [1]. Globally,
COPD is now the third leading cause of mortality [2] and
the second leading cause of disability-adjusted life-years
lost [3]. Acute exacerbations (defined as sustained wors-
ening of symptoms beyond the normal day-to-day variation
that may result in a change of medical treatment and/or
hospitalisation) represent one of the primary manifestations
of COPD and account for 50–75 % of the costs associated
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with disease [4]. More frequent exacerbations increase the
risk of hospitalisation, contribute to increased mortality
risk during hospitalisation and are associated with faster
decline in lung function and worsening health-related
quality of life [1, 5, 6].
The Evaluation of COPD Longitudinally to Identify
Predictive Surrogate Endpoints (ECLIPSE) study proposed
that frequent exacerbators are a distinct phenotype in the
moderate–severe stages of the disease that is relatively
stable over time [7, 8]. More specific phenotyping of
COPD appears an increasingly important step towards
improving clinical management [8]. Despite clearer
recognition of the frequent exacerbator phenotype, the
underlying biology of the susceptibility to exacerbations
remains unclear [9]. In order to better understand the
pathogenesis of exacerbations, comparisons of patients
with no versus frequent exacerbations are required [10]. As
a result of the identification of large alterations in immune-
related gene expression within the blood of frequent
exacerbators [11], researching the pathophysiology of
COPD exacerbations by focusing on changes that occur in
the systemic immune compartment rather than a specific
pulmonary immune defect per se could be fruitful.
Neutrophils, particularly neutrophil-derived pro-
teinases, have been implicated in lung destruction and
remodelling and hence pathogenesis of COPD [12].
Neutrophil count and neutrophilic inflammatory mediators
are higher within the airways, even in the stable (non-
exacerbated) state in COPD [13]. Blood neutrophils also
show an altered pattern of activity in the stable state in
COPD, with impaired chemotaxis and reduced intracel-
lular reactive oxygen species (ROS) production [14–16].
Evidence of further systemic immune dysregulation
occurs during exacerbations with circulating neutrophils
displaying up-regulation of inflammation-related genes,
enhanced expression of cell adhesion molecules and ele-
vated production of elastase and ROS [17–20]. Despite an
abundance of data supporting the hypothesis that neu-
trophils are key effector cells in the development and
progression of COPD [13], we could find no studies
assessing blood neutrophil function of COPD patients
according to exacerbation history.
To better establish the biological underpinning of the
frequent exacerbator and ultimately direct development of
novel therapies for this high-risk group of patients, we need
an improved understanding of the changes in systemic
immune function associated with this phenotype. With this
in mind, this proof-of-concept study was designed to
characterise blood neutrophil function of COPD patients in
a stable state with or without a history of frequent exac-
erbations. The primary aim of this study was to test the null
hypothesis that there is no difference in in vitro blood
neutrophil function between COPD frequent exacerbators,
COPD non-exacerbators and healthy controls.
Methods
Study Design and Participants
Following loco-regional ethics approval, 44 patients with
COPD, defined as over 40 years, at least 10-pack-year
smoking history and post-bronchodilator (100 mcg of
inhaled salbutamol) FEV1\80 % predicted with FEV1/
FVC ratio\0.70 [1], were prospectively recruited from
outpatient clinics of a UK district hospital.
Current symptoms (cough, sputum), exacerbation his-
tory, co-morbidities, prescribed medications and smoking
history were collected at interview. Participants underwent
clinical examination and spirometry (Vitalograph Alpha,
Vitalograph Ltd., UK). Frequent exacerbators were patients
who had 2 or more exacerbations requiring oral corticos-
teroids and/or antibiotics during the last 2 years, and/or
attendance to hospital [1]. Patients were deemed non-ex-
acerbators if they had not attended hospital nor required
systemic treatments for their COPD during the previous
2 years. Self-reports were confirmed through hospital
records and GP prescriptions. Eight healthy, ex-smokers
who had no symptoms of lung disease and had normal
spirometry were recruited as a control (reference) group.
Informed consent was obtained from all individual partic-
ipants included in the study.
We excluded current smokers defined as anyone reporting
smoking a cigarette within 6 months or having an exhaled
carbon monoxide (eCO)[10 parts per million (MicroCO,
CareFusion Ltd., UK) on the day of testing. We also excluded
anyone with known structural lung disease (asthma,
bronchiectasis, pulmonary fibrosis); cancer (other than non-
melanotic skin cancer); severe renal failure (calculated eGFR
less than 60 ml/min) or liver failure; immunodeficiency or
autoimmune conditions; anyone prescribed long-term antibi-
otics (including azithromycin), aminophylline, maintenance
oral steroids or other immunosuppressive medications. We
included patients prescribed inhaled corticosteroids (ICS),
anticholinergics and long- and short-acting beta agonists. All
patients were prescribed optimal medication for their COPD
according to current guidelines [1] and all were deemed
clinically stable with none reporting a worsening of symp-
toms (no exacerbation) in the previous 3 months.
Sample Collection and Haematological Analysis
Participants provided 10 ml of blood (K3EDTA and
lithium heparin) from the antecubital vein. Total and
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differential leukocyte counts and platelets were recorded
on K3EDTA anticoagulated whole blood using an auto-
mated haematology analyser (ADVIA 2120, Siemens
Healthcare Diagnostics GmbH, Eschborn, Germany).
Neutrophil Assays
As described previously [21], neutrophil phorbol-12-
myristate-13-acetate (PMA)- and formyl-methionyl-leucyl-
phenylalanine(fMLP)-stimulated oxidative burst were
assessed by a chemiluminescence (CL) kit (ABEL04 M,
Knight Scientific Ltd, Plymouth, UK) incorporating the
light-emitting protein Pholasin. The CL per well was
measured by a microplate luminometer (FLUOstar
OPTIMA, BMG Labtech, Aylesbury, UK). Each well
contained 10 lL of diluted whole (K3EDTA) blood (ratio
of 1:100 with Hank’s balanced salt solution; HBSS, with-
out calcium and magnesium), 90 lL assay buffer (HBSS
with calcium and magnesium), 50 lL Pholasin and 20 lL
adjuvant K. These mixtures were gently shaken and incu-
bated at 37 C for 30 s in the luminometer, prior to the
addition of 20 lL of PMA (5 lg/mL), 20 lL fMLP
(10 lM) (or additional 20 lL of HBSS for unstimulated
wells) to provide an end total volume of 200 lL per well, a
1:1010 final blood dilution and stimulated wells containing a
PMA or fMLP concentration of 0.5 lg/mL or 1 lM. These
concentrations have been standardised to be not rate limit-
ing, even in the presence of abnormally high numbers of
leukocytes, and thus provide responses that are reproducible.
For PMA, CL of stimulated and unstimulated replicates of
the same samples was recorded as relative light units (RLU)
at 20-s intervals for 30 min. For fMLP, CL was recorded
every second for 300 s. The area under the unstimulated CL
curves was subtracted from stimulated curves of the same
sample to determine PMA- or fMLP-stimulated oxidative
burst. To calculate responses on a per-cell basis in whole
blood, area under the CL curve was expressed as the number
of neutrophils (in well) only as the contributions of mono-
cytes, eosinophils and basophils in our 1:1010 final dilution
of blood are considered to be insignificant [21, 22].
Neutrophil-stimulated degranulation was determined as
previously described [23]. Heparinised blood (1 mL) was
added to a microcentrifuge tube with 50 lL bacterial
stimulant containing Staphylococcus aureus, Pseudomonas
fluorescens and Aerobacter aerogenes (840-15, Sigma,
Poole, UK). The microcentrifuge tubes were initially
mixed by gentle inversion before incubation at 37 C for
1 h (all tubes also mixed halfway through). Following
incubation, the tubes were centrifuged for 2 min at
16,000 g, with the supernatant being immediately removed
and stored at -80 C until further analysis. Following
thawing at room temperature, a1-proteinase inhibitor (a1-
PI)/neutrophil elastase (NE) complex was measured in all
samples using an ELISA kit (Calbiochem, Merck,
Darmstadt, Germany). Bacterial-stimulated degranulation
was based on subtracting a1-PI/NE of unstimulated sam-
ples (heparinised plasma at the same time point) away from
the stimulated samples and expression per neutrophil.
Statistical Analysis
Statistical analysis was performed using SPSS (v21.00;
SPSS Inc., Chicago, IL, USA). Normality was tested using
the Shapiro–Wilk test, and statistical significance was set at
p\ 0.05. Primary outcome measures were stimulated
neutrophil function. Data were analysed between groups
using one-way analysis of variance and independent t tests
or Kruskal–Wallis and Mann–Whitney U tests. Relation-
ship between baseline neutrophil count and daily
beclomethasone dose with neutrophil function were
assessed using Pearson correlation. For categorical data
(gender), Fisher’s exact test was applied.
Results
Clinical Characteristics and Blood Leukocytes
Clinical details and total and differential leukocyte counts
are summarised in Table 1. As expected, FEV1 was sig-
nificantly greater in healthy controls compared to both
COPD groups (p\ 0.001). No significant differences were
found between COPD frequent exacerbators and non-ex-
acerbators in FEV1, prescribed daily beclomethasone
equivalent dose and leukocyte counts (p[ 0.05).
Neutrophil Oxidative Burst
Both COPD frequent exacerbators and non-exacerbators
had lower fMLP-stimulated oxidative neutrophil burst
compared to controls, with frequent exacerbators also
showing significantly lower function compared to non-ex-
acerbators (Fig. 1).
Neutrophil PMA-stimulated oxidative burst was signif-
icantly lower in both COPD groups compared to controls
(Fig. 2). However, there was no significant difference
between COPD frequent exacerbators and non-exacerba-
tors for responses to PMA (p = 0.45). To help determine
the effect of baseline inflammatory status on subsequent
neutrophil responsiveness, we investigated whether ICS
exposure or baseline blood neutrophil count correlated with
measures of neutrophil function. There were no correla-
tions between fMLP-stimulated response and baseline
neutrophil count (p = 0.42), or between fMLP-stimulated
response and daily beclomethasone equivalent dose
(p = 0.17). There were no correlations between PMA-
Lung (2016) 194:881–887 883
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stimulated oxidative burst and baseline neutrophil count
(p = 0.791) or between PMA-stimulated responses and
daily beclomethasone equivalent dose (p = 0.30).
Neutrophil Degranulation
Blood neutrophils of COPD frequent exacerbators showed
heightened bacterial-stimulated degranulation (a1-PI/NE
complex) compared to non-exacerbators (Fig. 3). Although
there was no correlation between baseline neutrophil count
and stimulated concentrations of a1-PI/NE complex
(p = 0.880), there was a significant positive correlation
between daily beclomethasone equivalent dose and bacte-
rial-stimulated degranulation (p = 0.04, r = 0.298).
Discussion
In the present study, we showed that blood neutrophil
oxidative burst is blunted in COPD with receptor-depen-
dent ROS production showing greater impairment in the
frequent exacerbator phenotype. Assessment of total
degranulation responses of blood neutrophils showed fur-
ther dysregulation associated with the exacerbator
phenotype.
To the best of our knowledge, this is the first report on
the distinct patterns of neutrophil function that relate to
COPD exacerbation phenotype whilst in a stable state. We
do not prove mechanistically that changes in neutrophil
effector functions are the causes of or the results of fre-
quent exacerbations but provide an important starting point
for future investigations.
Table 1 Clinical characteristics of study participants
Parameter Healthy control
(n = 8)
COPD non-exacerbator
(n = 18)
COPD frequent exacerbator
(n = 26)
p value
Age (years) 63.3 ± 7.6 68.7 ± 7.7 65.0 ± 7.5 0.15
Males/females (n) 6/2 11/7 17/9 0.80
FEV1 (L) 2.7 ± 0.4 1.0 ± 0.3 1.0 ± 0.5 \0.01
FEV1 (% predicted) 89.7 ± 8.5 38.5 ± 10.8 36.6 ± 13.4 \0.01
Daily beclomethasone equivalent
(lg)
800 (0, 2000) 1500 (950, 2000) 0.14
Total leukocytes (109 L-1) 7.0 (6.3, 7.7) 9.1 (6.9, 10.7) 7.1 (6.2, 8.9) 0.13
Neutrophils (109 L-1) 4.0 (3.7, 4.7) 6.0 (4.3, 7.4) 4.6 (4.0, 6.3) 0.05
Monocytes (109 L-1) 0.5 (0.4, 0.7) 0.5 (0.4, 0.6) 0.5 (0.3, 0.8) 0.70
Total lymphocytes (109 L-1) 1.7 (1.6, 2.1) 1.7 (1.2, 2.2) 1.6 (1.0, 2.1) 0.51
Neutrophil:lymphocyte ratio 2.3 (1.8, 2.9) 3.6 (2.6, 5.1) 3.2 (2.0, 4.8) 0.06
Platelets (109 L-1) 236 (221, 333) 284 (246, 389) 289 (238, 380) 0.53
Data are presented as mean ± standard deviation or median (interquartile range). FEV1 forced expiratory volume in 1 s
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Fig. 1 Neutrophil fMLP-stimulated oxidative burst (chemilumines-
cence) responses. Columns indicate mean values for each group.
Error bars represent standard deviation. Significant difference
between groups: *p\ 0.05, **p\ 0.01, ***p\ 0.001
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Fig. 2 Neutrophil PMA-stimulated oxidative burst (chemilumines-
cence) responses. Columns indicate mean values for each group.
Error bars represent standard deviation. Significant difference
between groups: **p\ 0.01, ***p\ 0.001
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This study supports previously reported evidence of
reduced intracellular oxidative burst to fMLP in COPD
populations compared to healthy counterparts [15, 24].
Impaired chemotactic responses to fMLP have also been
observed in moderate–severe COPD, compared to healthy
smokers and non-smokers as well as COPD patients with
milder airflow obstruction [16]. These impaired functional
responses to stimulants are consistent with poor resistance
to infection in COPD. Like us, some other studies suggest
that greater severity of disease is not related with aug-
mented activity of inflammatory cells but a down-regula-
tion. Our study, however, suggests that there are certain
clinical phenotypes, which show further changes in neu-
trophil responses to inflammatory stimuli (bacterial pep-
tides) that may partly explain their intrinsic susceptibility
to recurrent infectious episodes. Blood neutrophils in
COPD demonstrate reduced migratory accuracy towards
fMLP and decreased structural changes and sensitivity to
such chemotactic factors under receptor occupancy [14].
Aberrant blood neutrophil responses in COPD appear to be
due to intrinsic cell defect (e.g. intracellular enzymatic
reactions and kinases) rather than cell surface expression of
chemoattractant receptors [14]. Further investigation (util-
ising whole blood flow cytometry) of immune regulation
events upstream (e.g. at the level of FPR1 receptor) and
downstream of neutrophil activation would help understand
the interpretation and significance of impaired fMLP-
stimulated oxidative burst in the frequent exacerbator.
Our findings of reduced blood neutrophil PMA oxidative
burst in COPD contrast with earlier reports of greater ROS
production compared to controls [25, 26]. Differences in
results could be explained by study participants (including
the differences in treatment (e.g. non-ICS users in [25, 26])
or characteristics of the sampling and assays. For example,
Renkema et al. [25] used heparinised samples (as opposed
to EDTA), which have been demonstrated to interfere with
neutrophils prior to subsequent activation of oxidative
burst [27, 28]. Previous studies [25, 26] had also used
isolation procedures that are known to influence neutrophil
activation (including density gradient centrifugation, fluc-
tuations in temperature) prior to any staining and in vitro
stimulation. Our approach, using whole blood, provides
minimal manipulation of cells and provides a more accu-
rate representation of neutrophil behaviour in vivo (i.e.
better maintenance of the extracellular milieu) [29]. In
contrast to fMLP, we did not observe differences between
exacerbation phenotypes in PMA-stimulated oxidative
burst. Unlike the G-coupled receptor-dependent responses
to fMLP, PMA penetrates the cell (independent of a
receptor), triggering a long-lasting, strong stimulation via
protein kinase C and activation of NADPH oxidase
throughout the cell. PMA is considered an artificial stim-
ulus (not encountered in vivo), differing substantially from
physiological agonists (e.g. fMLP) [30]. Although PMA-
stimulated responses provides further evidence of the
aberrant intracellular signalling in COPD, such cell acti-
vation lacked biological sensitivity to characterise COPD
phenotypes that may differ in their ability to recognise
microbial moieties (e.g. formylated peptides) and mount
responses toward infectious/inflammatory challenge [31].
COPD blood neutrophils possess exaggerated innate
immune responses to Toll-like receptor (TLR) agonists
(e.g. lipopolysaccharide) [32]. Upon triggering neutrophil
degranulation, the concentration of free NE increases for
only a brief period of time as its major inhibitors (e.g. a1-
PI) rapidly reach equimolar concentrations [33]. Mea-
surement of a1-PI/NE complexes is considered to be a
marker of total NE release during neutrophil degranulation
[34]. Here, we suggest that such heightened responses to
TLR agonists (in our case both gram-positive and gram-
negative bacteria) are more reflective of a COPD frequent
exacerbator. These findings appear contradictory to the
data on fMLP, whereby both fMLP-stimulated oxidative
burst (e.g. FRP1) and bacterial-stimulated degranulation
(e.g. TLR2, TLR4) represent receptor-mediated events.
Similar differences between circulating phagocyte respon-
ses to chemoattractants and pro-inflammatory mediators
have been observed in COPD [35]. Although distinct and
complex intracellular transduction pathways are involved,
one plausible mechanism for the observed variability
between neutrophil effector functions in our study is the
selective effect of ICS on one of the neutrophil function
pathways (a1-PI/NE). In COPD patients stratified accord-
ing to GOLD severity, increasing ICS dosage was associ-
ated with enhanced stimulated neutrophil degranulation
[36]. Budesonide and fluticasone propionate prolong
human neutrophil survival by inhibiting apoptosis at clin-
ically relevant drug concentrations [37]. We speculate that
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the greater (albeit non-significant) mean beclomethasone
exposure of the frequent exacerbators may partly explain
the heightened NE release of stimulated blood neutrophils
in the frequent exacerbator.
Strengths of our study include its real-life setting using
recognised clinical phenotypes of COPD. Our findings are
generalisable with patient demographics reflecting patients
with moderate-to-severe disease that attend a standard
secondary care service. The greater proportion of patients
prescribed ICS in frequent exacerbators corroborates pre-
vious findings [11] and reflects current treatment guidelines
[1]. The number of participants in our study is comparable
to most other biological studies comparing neutrophil
responses in COPD. We also validated and controlled for
smoking status and used a healthy control group as an
additional reference point.
The cross-sectional methodology does not allow us to
identify whether responses of the frequent exacerbator
represent an intrinsic or acquired defect of neutrophil
function. The primary aim of this study was to characterise
blood neutrophil function (in the stable state) in COPD
exacerbation phenotypes and not the temporal nature of the
relationship between inflammatory mediators and onset of
COPD exacerbations investigated previously [38]. We did
not sample airway neutrophils to compare against blood;
however, others propose that the dysregulation of immune
function in COPD frequent exacerbators may be systemic
rather than a specific abnormality limited to the lungs [12].
Conclusions
In conclusion, we have demonstrated aberrant blood neu-
trophil functions in COPD, highlighting alterations in
receptor-dependent responses that relate to the frequent
exacerbator phenotype. Frequent exacerbators have
impaired oxidative responses to chemotactic factors and
augmented degranulation responses to bacterial triggers in
the circulation. Importantly, this study provides further
support to a biological underpinning of the frequent exac-
erbator phenotype and provides insights into immune cell
defects that can act as the basis for future investigations.
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